These observations advocates the possibility that inhibiting IDH mutants might reverse their tumorigenic effects [77] and that the design of effective inhibitors would need to take into account the complex downstream effects of IDH mutations.Recently, to assess this therapeutic possibility in the glioma context, Rohle et al. [78] used AGI-5198, a small molecule inhibitor of the most common IDH mutation in gliomas, IDH1-R132H. Here, IDH1 is linked to central nervous system cancer.